Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37516849)

  • 1. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.
    Muhammad S; Fan T; Hai Y; Gao Y; He J
    Mol Cancer; 2023 Jul; 22(1):121. PubMed ID: 37516849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-2 therapy of cancer-clinical perspectives.
    Majidpoor J; Mortezaee K
    Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology of the interleukin-2 receptor.
    Nelson BH; Willerford DM
    Adv Immunol; 1998; 70():1-81. PubMed ID: 9755337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of IL-2 and IL-2R SNPs on proliferation and tumor- killing activity of lymphokine-activated killer cells from healthy chinese blood donors.
    Li Y; Meng FD; Tian X; Sui CG; Liu YP; Jiang YH
    Asian Pac J Cancer Prev; 2014; 15(18):7965-70. PubMed ID: 25292096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The circadian rhythm key gene
    Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
    Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.
    Ritu ; Chandra P; Das A
    Clin Exp Med; 2023 Dec; 23(8):4297-4322. PubMed ID: 37804358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel role of metalloproteinase in cancer-mediated immunosuppression.
    Sheu BC; Hsu SM; Ho HN; Lien HC; Huang SC; Lin RH
    Cancer Res; 2001 Jan; 61(1):237-42. PubMed ID: 11196168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
    Nagaoka K; Shirai M; Taniguchi K; Hosoi A; Sun C; Kobayashi Y; Maejima K; Fujita M; Nakagawa H; Nomura S; Kakimi K
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8
    Hernandez R; Toomer KH; Põder J; Santos Savio A; Hsiung S; Malek TR
    Cancer Immunol Immunother; 2021 Apr; 70(4):909-921. PubMed ID: 33037893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rethinking Oncologic Treatment Strategies with Interleukin-2.
    Ko B; Takebe N; Andrews O; Makena MR; Chen AP
    Cells; 2023 May; 12(9):. PubMed ID: 37174716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological effects of IL-21 on immune cells and its potential for cancer treatment.
    Ma M; Xie Y; Liu J; Wu L; Liu Y; Qin X
    Int Immunopharmacol; 2024 Jan; 126():111154. PubMed ID: 37977064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.